Received Jun 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
pharmacist who said a patient received a dose of GARDASIL 9 "last August" and came back to get his second shot of the series last week.; no adverse event; This spontaneous report was received from a pharmacist and refers to a 29-year-old male patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. In August 2024, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), Injection; In May 2025, also reported as last week, the patient came back to get his second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) ( for both doses, lot #, dose, route of administration, anatomical location of vaccine and expiration date were not reported) for Prophylaxis (inappropriate schedule of vaccine administered). No additional adverse event was reported.